Previous 10 | Next 10 |
Immuno-oncology leader, Agenus Inc. (“Agenus”) (Nasdaq: AGEN), today announced a data update from the phase 1 expansion cohort of botensilimab (multifunctional CTLA-4 antibody) in combination with balstilimab (PD-1 antibody) for patients with advanced, refractory sarcomas has been s...
Company Announces Participation in BTIG Virtual Biotechnology Conference Immuno-oncology leader, Agenus (Nasdaq: AGEN), today announced the Company will release its second quarter 2023 financial results via press release before the market opens on Tuesday, August 8, 2023. In addition,...
Robin Taylor, MBA, Ph.D., Appointed Chief Commercial Officer Homa Yeganegi Appointed Chief Product Strategy and Global Medical Affairs Officer Stephanie Fagan Appointed Chief Communications Officer Immuno-oncology leader, Agenus Inc. (“Agenus”) (Nasdaq: AGE...
Median Overall Survival of 20.9 Months for Patients Without Active Liver Metastases Surpasses the Recently Reported 12.9-Month Benchmark with Standard of Care in this Population Immuno-oncology leader, Agenus (Nasdaq: AGEN), shared promising data today from its Phase 1b trial on the bot...
2023-06-05 11:38:01 ET Summary Agenus Inc. has existed for a long three decades, doing nothing much really. They have been producing very strong data from botensilimab lately. Agenus Inc. prospects could now change for the better. My beef against Agenus Inc. ( ...
AGEN2373 is the first CD137 agonist antibody reporting single agent responses with no major toxicity Responses reported in patients with prostate cancer, ampullary carcinoma and metastatic vulvar squamous cell carcinoma No hepatic toxicities, grade ≥3 treatment-related adverse even...
Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of clinical and preclinical-stage cancer treatments, today announced that Dr. Garo Armen, Chairman and CEO, will participate in a fireside chat and investor one-on-ones at the upcoming Jefferies Healthcare Conference o...
2023-05-09 19:00:34 ET Image source: The Motley Fool. Agenus (NASDAQ: AGEN) Q1 2023 Earnings Call May 09, 2023 , 8:30 a.m. ET Operator Continue reading For further details see: Agenus (AGEN) Q1 2023 Earnings Call Transcript
2023-05-09 11:33:10 ET Agenus Inc. (AGEN) Q1 2023 Earnings Conference Call May 9, 2023 08:30 AM ET Company Participants Zack Armen - Head, IR Dr. Garo Armen - Chairman & CEO Dr. Steven O'Day - Chief Medical Officer Christine Klaskin - Vice President of Fi...
2023-05-09 08:10:56 ET Agenus press release ( NASDAQ: AGEN ): Q1 GAAP EPS of -$0.22 misses by $0.01 . Revenue of $22.9M (-11.7% Y/Y) misses by $0.63M . At a late-breaking presentation at ASCO-GI, botensilimab/balstilimab combination demonstrated a 63% 12-month ...
News, Short Squeeze, Breakout and More Instantly...
Extended BOT/BAL Therapy Yields Pronounced Improvements in Tumor Reductions Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in developing novel immunological agents to treat various cancers, today announced results from an investigator-sponsored trial (IST) of botensilim...
Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in developing novel immunological agents to treat various cancers, today announced that the Cancer Therapy Evaluation Program (CTEP) is accepting Letters of Intent (LOIs) to conduct clinical studies using botensilimab (BOT), a huma...
2024-06-27 01:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...